U.S. District Court Rules in Favor of Lilly; Upholds Company's 2011 Patent on Zyprexa

INDIANAPOLIS, April 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) 2011 patent on Zyprexa(R), a breakthrough medicine for the treatment of schizophrenia and bipolar disorder. In the case of Eli Lilly and Company v. Zenith Goldline Pharmaceuticals et al., the court ruled in favor of Lilly on all accounts, including the patent doctrines of obviousness, double patenting, inequitable conduct, novelty, and public use. "We have always been very confident that our patents are valid and enforceable and today's court ruling sends a clear message on the strength of those patents," said Sidney Taurel, Lilly chairman, president and chief executive officer. "Protection of intellectual property rights is extremely important to the pharmaceutical industry and the physicians and patients it serves, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs." Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY Zyprexa(R) (olanzapine, Lilly) (Photo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ) SOURCE Eli Lilly and Company Phil Belt, +1-317-276-2506, or Terra Fox, +1-317-276-5795, both of Eli Lilly and Company http://www.prnewswire.com Copyright (C) 2005 PR Newswire. All rights reserved. News Provided by COMTEX

The release as fetched from its publisher. lilly.com ↗